EyePoint Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
19.9%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$3.82next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly223MTarget: Sufficient to fund operations into Q4 2027
DURAVYU Phase 3 wet AMD (LUGANO and LUCIA) Enrollment Status Quarterly100.0Target: 100% (Fully Enrolled)
DURAVYU Phase 3 DME (COMO and CAPRI) Enrollment Progress Quarterly35.0Target: 100% (Full Enrollment expected in Q3 2026)
Watch Items
- Topline data readout for Phase 3 LUGANO trial in wet AMDTrigger: Mid-2026 (expected beginning August 2026)Action: Evaluate clinical efficacy (non-inferiority to aflibercept), safety profile, and durability of 6-month dosing interval.
- Topline data readout for Phase 3 LUCIA trial in wet AMDTrigger: Shortly following LUGANO (expected late 2026)Action: Assess consistency of results across both pivotal trials to support planned NDA filing.
- Enrollment completion of Phase 3 COMO and CAPRI trials in DMETrigger: Q3 2026Action: Confirm timeline for topline DME data readout expected in H2 2027.
Research as of 20 Jun 2026